Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

HEM TEST 2024 > Benign hematology facts > Flashcards

Benign hematology facts Flashcards

1
Q

Definition of Transfusion independence in thalassemia

A

less than 6 PC in 6 months
no PC in previous 2 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Hb in Thalassemia intermedia

A

7-10 g%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Beta thalassemia intermedia genotype

A

Compound heterozygotes

Homozygotic to non severe mutations (b0/b+)
# Beta heterozygote with alpha gene excess
# Hemoglobin E/β-thalassemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Hereditary spherocytosis inheritance

A

AD 66%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Disease more common in NTDT

A

PHTN including RV dys
VTE
Silent cerebral ischemia
Cholelithiaisis
Leg ulcer
Splenomegaly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Luspa for NTDT

A

BEYOND study
improves Hb levels after 3 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Indications for iron chelation in NTDT

A

Ferritin level > 800 ng/mL
Liver iron concentration > 5 mg/g

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Hydrea in NTDT

A

improves Hb
may aid with PHTN/Extramedullary hematopoiesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Reasons to start transfusions in NTDT

A

PHTN
Extramedullary hematopoiesis
Worsening anemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Deferasirox in NTDT

A

PO
THALASSA trial
improved Hb in NTDT
Approved also for TDT
SE: GI, rash, LFT, increased Cre, loss of hearing, cataract
New formulation JADENU with less SE. Not approved in Israel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Differentiation between dose related drug associated mild neutropenia and agranulocytosis

A

Mild neutropenia is dose dependent- usually asymptomatic
Agranulocytosis is immune mediated and usually pts are febrile

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Mortality rates in agranulocytosis

A

7%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Ferrinject in HF pts with IDA

A

Did not show benefit
Results might have been effected by covid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Hereditary spherocytosis gene

A

ANK1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Hereditary spherocytosis prevalence

A

1/1000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

HS acute hemolytic complications

A

Neonatal jaundice
Megaloblastic crisis- due to folate def during pregnancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Iron overload parameters in HS

A

Ferritin >500 mg/l
Saturation >60%
Liver iron concentration >4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Renal complications of HS

A

Distal renal tubular acidosis
in Band3 mutated pts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

HS diagnosis

A

Screen-
# Osmotic fragility
# EMA- reduced bunding of EMA to band 3
confirm- Genetic testing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Contraindication for splenectomy in hereditary hemolytic anemias

A

Dehydrated hereditary stomatocytosis
Due to high thrombotic risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Stomatocytosis

A

Light wide transverse band in the middle of erythrocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Acquired stomatocytosis

A

Alcoholism
Hepatobiliary disease
Malignant neoplasms
CV disorders

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Rapidly progressive hemolytic
anemia in alcoholism

A

Zieve syndrome
Association with end-stage alcoholic cirrhosis
Acanthocytes are present

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

McLeod phenotype

A

Acanthocytes due to reduced kell antigen
X linked

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Rh deficiency (null) syndrome

A

Full or partial lack of Rh
causing mild hemolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Diagnosis of congenital enzymopathies and skeletal RBC abnormalities

A

Targeted NGS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Coombs negative AIHA %

A

10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Secondary warm AIHA etiologies
(5 causes)

A
  1. LY (CLL)
  2. AI (SLE)
  3. Non lymphoid cancers (ovarian tumors)
  4. Inflammatory diseases
    (UC)
  5. Drugs (Cephalosporins, NSAIDs)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Secondary CAD etiologies

A
  1. Postinfectious (Mycoplasma pneumoniae/EBV)
  2. LY
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

PCH etiology

A

Primary
Viral (pediatric)
Syphilis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

IgM target in CAD

A

I Antigen
i Antigen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

IgG target in PCH

A

P Antigen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Rituximab benefit in warm AIHA

A

Increases response rates
75% vs 30% in 1 year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Agents with activity as 2nd/3rd line in warm AIHA

A

MMF
Azathiprine
CY
CsA
Danazol
Bortezomib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Tapering doses in AIHA

A

Start tapering after 2-3 weeks
20 mg at 2 months
discontinuation not before 6 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Agents with activity in CAD

A

Bendamustine
Bortezomib
Ibrutunib
Sutimlimab

37
Q

Drug induced TMA agents

A

Mitomycin
Gemcitabine
Tacrolimus
Sirolimus
Quinine
Emicizumab
High doses of FEIBA

38
Q

Tx of Shiga toxin associated TMA

A

Eculizumab seems promising

39
Q

Agents causing direct damage to RBCs- resulting in hemolysis

A

Copper/Lead
Dapsone/Sedural/Ribavirin
Snake/Spider bites
Burns

40
Q

HbA2 levels diagnostic of b-thalasemia

A

> 3.5%

41
Q

TD beta thalassemia genotype

A

b0/b0
Severe HbE/b-thalassemia syndromes

42
Q

b-thalassemia NTDT beta thalasemia

A

b-thalassemia intermedia
Moderate HbE/b-thalassemia syndromes

43
Q

a-thalassemia silent carrier genotype

A

-a/aa

44
Q

a-thalassemia trait genotype

A

–/aa
-a/-a

45
Q

HbH genotype

A

–/-a

46
Q

TDT alpha thalassemia genotype

A

Severe types of HbH

47
Q

NTDT alpha thalassemia genotype

A

Mild-moderate types of HbH

48
Q

Hb electrophoresis in alpha thalassemia

A

Trait and silent carrier- normal
NTDT and TDT- 5-40% of HbH

49
Q

Chelation goal in TDT

A

Ferritin of <1000 ng/mL
LIC of <5
Cardiac T2* of >20 ms

50
Q

Deferoxamine

A

Tx of TDT thalassemia
SC or IV infusion
Continous infusion
SE: FTT, loss of hearing, retinopathy, yersinia infections, OP

51
Q

Deferiprone

A

Tx of TDT thalassemia
PO
SE: agranulocytosis!, GI, LFT, arthralgia, zinc deficiency

52
Q

Luspatercept for TDT

A

BELEIVE
Reduction in transfusion of 33%
increased VTE

53
Q

SCD genotype

A

HbSS, HbSb0-severe (causing anemia)
HbSC, HbSb+-mild

54
Q

Sickle cell trait complications

A

Splenic infarction at high altitude
Hematuria
Renal papillary necrosis Pyelonephritis during pregnancy

Medullary carcinoma of kidney
VTE

SHARP MT

pointy like the cells
dead

55
Q

Effect of a-thalassemia on SCD

A

Reduces hemolysis and risk of VTE

56
Q

Haplotype of S in SCD with worst prognosis

A

Central African Republic (CAR)

worsens when cold

57
Q

Differentiating HbSS and HbSB0

A

MCV

58
Q

Acute chest syndrome Sx

A

Similar to PNA

59
Q

Risk factors of developing acute chest syndrome

A

Young age
Low HbF
high WBC
High steady state Hb

60
Q

Leading cause of death in SCD

A

Acute chest syndrome

61
Q

Exchange transfusion indication in SCD with acute chest syndrome

A

Hypoxemia despite oxygen
Widespread infiltrates,
Rapid clinical deterioration.

62
Q

Preventive measures for acute chest syndrome in SCD

A

HU
Chronic RBC transfusions

63
Q

Silent cerebral infarcts in SCD %

A

30% children
50% adults

64
Q

Disease modifying Tx in SCD

A

HU
L-glutamine
Crizanlizumab
Voxelotor

65
Q

Benefit of HU in SCD

A

Reduces pain episodes, acute chest syndrome, and
transfusions

66
Q

L-glutamine benefit in SCD

A

Reduces pain crisis in addition to HU

67
Q

HbE

A

Trait- Asymptomtic
Homozygotes- mild microcytic anemia

68
Q

HbC

A

HbCC or HbC beta-thalssemia have mild anemia with splenomegaly

69
Q

Gaucher disease clinical manifestations

A

Hepatosplenomegaly
Cytopenias
Bone deformation and pain

70
Q

Gaucher disease diagnosis

A

Decreased glucocerebrosidase activity

71
Q

Gaucher disease Tx

A

Enzyme replacement therapy

72
Q

Incidence AIHA

A

2/100K

73
Q

Mortality AIHA

A

5%

74
Q

FP coombs

A

Allo Ab- 3 months from transfusion
Dara
IVIG
Sepsis- non specific Ab due to increased Ab in plasma

75
Q

Primary vs secondary AIHA %

A

50%-50%

76
Q

Which IgGs are clinically important for hemolysis

A

IgG1
IgG3

77
Q

Severe wAIHA necessitating rituximab

A

Hb <8
Transfusion
Evans
IgA

78
Q

Novel Tx in AIHA

A

Protesome inhibitors
CD38 i
Fosfamatinib
BTKi

79
Q

Nipo

A

Anti FcRn
Prevention of fetal hemolysis
Novel Tx of wAIHA with combination with PEX

80
Q

Cold agglutination titer

A

1/64

81
Q

Monoclonal in CAD %

A

80%
IgMk

82
Q

Complement inhibition in CAD

A

Sutimlimab
C1 inhibitor
In acute hemolysis
Bridging Tx to rituximab

83
Q

Alpha glowing chromosome

A

16

84
Q

Beta globin chromosome

A

11

85
Q

Hb goal in thalassemia

A

12

86
Q

Luspa SE

A

Bone pain
Extramedullary hematopoesis- consider imaging prior to Tx
May be teratogenic

87
Q

HbS goal of exchange transfusion independence SCD

A

HbS< 40%

88
Q

Cold agglutinin titer for CAD

A

64

89
Q

1st line Tx of choice for CAD

A

BR X4
60% CR with long DoCR
Time to best response is long (6-7 months)

R alone is also an option

HEM TEST 2024 (32 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions